PRKCE and neoplasm: Also a role as a tumor suppressor has been described for miR-205-5p in prostate [86, 87], breast [88], melanoma [89], glioblastoma [90] and colon cancers [91] by targeting cMYC [92], PKCε [86], and VEGF-A [90].